title: Evaluation of monoclonal antibody-based capture enzyme immunoassays for detection of specific antibodies to measles virus.
abstract: Monoclonal antibodies to the hemagglutinin protein, fusion protein, phosphoprotein, matrix protein, and nucleoprotein of measles virus were evaluated as detector antibodies in capture enzyme immunoassays (EIAs) for the detection of specific serum immunoglobulin G (IgG), IgA, and IgM antibodies to measles virus. A pool of monoclonal antibodies to hemagglutinin protein and nucleoprotein proved optimal and was further evaluated. Specific IgM was detected in 97% of adolescents with clinical measles, 97% of infants 3 weeks postvaccination, and less than 1% of normal serum specimens. Specific IgA antibodies were found in 97% of adolescents with clinical measles, 97% of infants 3 weeks postvaccination, and less than 1% of normal serum specimens. Specific IgA antibodies were found in 97% of clinical measles cases and vaccinees, in 26% of healthy persons, and in 36% of infants 8 months postvaccination; consequently, IgA antibodies were not a useful indicator of recent measles infection. A significant increase in IgG antibodies between paired specimens was detected in 92% of clinical cases and all vaccinees. Only 59% of infant specimens had persistent IgG antibodies as detected by capture EIA at 8 months postvaccination, whereas all specimens had antibodies as detected by hemagglutination inhibition and plaque neutralization. An alternative indirect EIA, in which antigen was directly absorbed to the solid phase, was more sensitive than the capture design, detecting IgG antibodies in all infants postvaccination. When standardized with a microneutralization assay for the detection of persistent antibodies, the indirect IgG EIA gave predictive values for positive and negative tests exceeding 90%. Our capture IgM and indirect IgG EIAs provide a practical combination of serologic tests for the determination of acute measles virus infection and past exposure to measles virus or vaccine, respectively.
authors.affiliation: Respiratory and Enterovirus Branch, Centers for Disease Control, Atlanta, Georgia 30333.
authors.forename: D D
authors.initials: DD
authors.lastname: Erdman
authors.forename: L J
authors.initials: LJ
authors.lastname: Anderson
authors.forename: D R
authors.initials: DR
authors.lastname: Adams
authors.forename: J A
authors.initials: JA
authors.lastname: Stewart
authors.forename: L E
authors.initials: LE
authors.lastname: Markowitz
authors.forename: W J
authors.initials: WJ
authors.lastname: Bellini
mesh_terms: D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral / Q000097:blood*; D000918:Antibody Specificity; D005069:Evaluation Studies as Topic; D006801:Humans; D007124:Immunoenzyme Techniques; D007070:Immunoglobulin A / Q000032:analysis; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D008457:Measles / Q000276:immunology; D008458:Measles Vaccine / Q000276:immunology; D008459:Measles virus / Q000276:immunology*; D009500:Neutralization Tests
chemical_list: D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D008458:Measles Vaccine